Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios.
about
Investigating the structural plasticity of a cytochrome P450: three-dimensional structures of P450 EryK and binding to its physiological substrate.Integrase Inhibitor Prodrugs: Approaches to Enhancing the Anti-HIV Activity of β-Diketo AcidsKinetic deuterium isotope effects in cytochrome P450 oxidation reactionsDevelopmental pharmacokinetics in pediatric populationsITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humansMultiple UDP-glucuronosyltransferases in human liver microsomes glucuronidate both R- and S-7-hydroxywarfarin into two metabolites.Investigation by site-directed mutagenesis of the role of cytochrome P450 2B4 non-active-site residues in protein-ligand interactions based on crystal structures of the ligand-bound enzymePrediction-driven matched molecular pairs to interpret QSARs and aid the molecular optimization processStructure and Protein-Protein Interactions of Human UDP-GlucuronosyltransferasesApplication of multi-target phytotherapeutic concept in malaria drug discovery: a systems biology approach in biomarker identificationDosing Recommendations for Concomitant Medications During 3D Anti-HCV TherapyUnderstanding a substrate's product regioselectivity in a family of enzymes: a case study of acetaminophen binding in cytochrome P450sA novel anti-HIV active integrase inhibitor with a favorable in vitro cytochrome P450 and uridine 5'-diphospho-glucuronosyltransferase metabolism profile.Contributions of human enzymes in carcinogen metabolismA new approach to predicting human hepatic clearance of CYP3A4 substrates using monkey pharmacokinetic data.Predicting Mouse Liver Microsomal Stability with "Pruned" Machine Learning Models and Public Data.Predicting in vivo drug interactions from in vitro drug discovery data.Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidationAssessment of the pharmacokinetic interaction between eltrombopag and lopinavir-ritonavir in healthy adult subjects.Data-driven methods to discover molecular determinants of serious adverse drug events.Comprehensive characterization of cytochrome P450 isozyme selectivity across chemical libraries.Comparison of the Inhibitory Potential of Bavachalcone and Corylin against UDP-Glucuronosyltransferases.Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases.Improving the oral bioavailability of beneficial polyphenols through designed synergies.Glucuronidation of drugs and drug-induced toxicity in humanized UDP-glucuronosyltransferase 1 mice.A novel humanized mouse lacking murine P450 oxidoreductase for studying human drug metabolism.Identification of diet-derived constituents as potent inhibitors of intestinal glucuronidation.Decision tree models for data mining in hit discovery.Evaluation of metabolism-mediated herb-drug interactions.A quantitative high-throughput 96-well plate fluorescence assay for mechanism-based inactivators of cytochromes P450 exemplified using CYP2B6.Effects of rifampin and ketoconazole on pharmacokinetics of morinidazole in healthy chinese subjectsAntiepileptic drug interactions - principles and clinical implications.Recent Structural Insights into Cytochrome P450 Function.Molecular probes of the mechanism of cytochrome P450. Oxygen traps a substrate radical intermediateEffects of acetaminophen, naproxen, and acetylsalicylic acid on tapentadol pharmacokinetics: results of two randomized, open-label, crossover, drug-drug interaction studies.Computer-aided retrometabolic drug design: soft drugs.No interacting influence of lavender oil preparation silexan on oral contraception using an ethinyl estradiol/levonorgestrel combinationThe development of UDP-glucuronosyltransferases 1A1 and 1A6 in the pediatric liverThe effect of gut microbiota on drug metabolism.Inhibition of human cytochrome P450 3A4 by cholesterol
P2860
Q24652426-824967BF-9192-43DB-A950-00B990F5DEAAQ26800036-4230C4F8-83C0-4D33-815D-8ADDB10B8578Q26830634-59069F99-FDA2-4D2B-A70C-231C51B29AB5Q27002933-266EF7B2-43B9-486D-8B26-780C63C94246Q27022933-8AFB760B-79FF-4E2F-9475-0E1F63C7BA76Q27334876-FEC62B2E-D331-491D-B05A-9EE11F394594Q27675363-9819E6AD-B9F4-4C9B-8206-F0161AFF305CQ27902343-422D8B16-57E6-4DAF-9E9F-E7BDBEC09C04Q28071266-6CF6FD40-E11E-4856-88D7-45FA08DEFF28Q28077952-3A8315B7-7D47-466A-A60F-64BB670913D1Q28080752-C555640C-7B46-4E28-B3DE-C0D7E296DECEQ28539428-A02D3BF4-EB10-446F-A8F2-24D1E0566B24Q30429621-CD66BFBE-E218-4472-B3BA-0797D6F41638Q30520640-CE3F632A-96C1-40A5-88D1-6055C9C9D3EAQ30577525-BB87E9FB-5526-4152-A6E4-36573EBCA98CQ30998741-A510EC33-1DAD-47E4-993C-5295923DD1A9Q31011412-8F71A44D-D505-4662-BE45-857AC42DD9BCQ31034463-560D0A40-C61A-4912-BBC4-2EE324F8C720Q33400092-F74837B9-3060-4613-B7BA-34C6ED2E38CAQ33403734-6E5B4296-9B02-44EF-AD61-C1EDB42EC822Q33512310-7290B797-2B6F-450F-A361-A3E265EC2545Q33562840-369B4D8C-9FD6-4F67-92B5-8371A4FC1FE4Q33574627-9B4A0F31-79C0-4E49-8B47-F170F3B62795Q33646033-39BE03D3-7630-4CF7-B4DE-7FEB616E32C2Q33742730-56DB88B9-3DFB-4154-8557-02E233C912B5Q33849042-03B56AC7-33B1-4DFD-B708-DC9D9A115CD5Q34185989-37178AEC-1840-4E0D-BE73-876AA0412B86Q34212628-3F66B91E-BB4F-4EC7-82F0-0ABFF5676086Q34238039-73274AC0-EBFB-4D8B-B11B-5392228EF176Q34256839-DF2B12EB-B8B8-41B1-8AC0-D15FD7AC9D80Q34299005-CBB85661-A471-4831-981B-5ED1B9EDB2B9Q34402188-38EA1D48-9EAE-4C41-9AE6-501F99D46488Q34529849-16568CC0-ED5A-48DA-AA73-5824AD4E4420Q34586651-1ABF1FC5-81C7-413B-BA5D-645C9E3C8D81Q34615173-157FE214-C7B2-401E-A842-F3760AD5F7C7Q34619242-7120F4A5-24F5-49B3-9187-8D34FD1F6B02Q34727805-12A80DEB-FE3F-482D-8202-E7D78E80BA53Q34857030-5B9EAB1C-D448-4E2C-BC15-BABB8D106932Q34986604-22B9E313-84F3-4F9D-805F-4DEDB408B00EQ34998005-EB93A46F-415A-4A63-97FB-199D36BFC529
P2860
Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Drug-drug interactions for UDP ...... ow exposure (AUCi/AUC) ratios.
@ast
Drug-drug interactions for UDP ...... ow exposure (AUCi/AUC) ratios.
@en
type
label
Drug-drug interactions for UDP ...... ow exposure (AUCi/AUC) ratios.
@ast
Drug-drug interactions for UDP ...... ow exposure (AUCi/AUC) ratios.
@en
prefLabel
Drug-drug interactions for UDP ...... ow exposure (AUCi/AUC) ratios.
@ast
Drug-drug interactions for UDP ...... ow exposure (AUCi/AUC) ratios.
@en
P2093
P356
P1476
Drug-drug interactions for UDP ...... ow exposure (AUCi/AUC) ratios.
@en
P2093
Barry C Jones
Dennis A Smith
J Andrew Williams
Jeffrey R Koup
Ruth Hyland
Simon E Ball
Susan Hurst
Theunis C Goosen
Vincent Peterkin
P304
P356
10.1124/DMD.104.000794
P577
2004-08-10T00:00:00Z